CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team's dedication unveils insights on payload properties, shaping the future of ADC therapies. A crucial leap in cancer treatment. We are proud to announce our significant...

CancerAppy's groundbreaking study at ESMO Congress (Oct '23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common transcripts and potential predictors, our AI-driven research shapes the future of cancer treatment.CancerAppy has...

We are delighted to announce our first collaborative scientific research article. At CancerAppy, our commitment to harnessing the power of AI in cancer drug discovery has led us to join forces with leading researchers in the field. This groundbreaking collaboration...

Cancerappy participated in the II international congress organized by ATG Symbio Spain that was held inBarcelona at the Biomedical Research Park (PRBB) on July 1 and 2, 2023.Our CEO had the opportunity to present our company and show our latest advances in the NMEs...

Our CEO will be attending the BIO International in Boston from June 5th to 8th. Cancerappy is dedicated to the discovery and development of new AI-based pharmaceuticals. Currently, we have a strong pipeline that validates and demonstrates our value proposition. If you...

From 15th to 18th of May, our CEO and CMO will be attending various international events in Hong Kong introducing the latest advances of our company. They will attend Asia Summit on Global Health, Invest in Honk Kong #investHK, and different meeting with local...

Our CEO Luis Martín Ezama will be attending the #Meet2win23 event 11th and 12th of May, exposing the characteristics of our pipeline of new cancer drugs. We are developing first-in-class antibodies and small molecules against solid tumors.

April 20th. We are going to attend the 19th Annual Anglonordic Life Science Conference.Meet us to discuss face to face about our latest works: CA04 first-in-class monoclonal antibody, CA05 first-in-class kinase inhibitor and CA07 novel PROTAC.We can’t wait to hear...

Cancerappy, together with UCLM, has been awarded the grant from the CCP21 program for the development of nanomedicines (nanoPROTACs), with a total budget of €757,000 and a project duration of 3 years.